WALTHAM, Mass., May 11, 2020 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science,
today announced it is expanding capacity for viral vector
development and manufacturing services with construction of a new
commercial manufacturing site in Plainville, Mass. The $180 million project will more than double the
company's commercial viral vector capacity to support increasing
demand for the development and manufacture of gene therapies and
vaccines.
Construction of the new 290,000-square-foot facility is expected
to be completed in 2022. The project will add more than 200 jobs
and complement the company's new or recently expanded capacity in
Lexington and Cambridge, Mass., and Alachua, Fla.
"The Plainville expansion
significantly enhances our 'start here, stay here' strategy,
ensuring that customers have an uninterrupted pathway from
development through commercialization," said Michel Lagarde, executive vice president of
Thermo Fisher Scientific. "Between Plainville and our other
expanded sites in the U.S., we're increasing viral vector
production to accelerate cell and gene therapy innovation, giving
hope to more patients everywhere."
The Plainville site will offer
a flexible and scalable configuration of laboratory and production
suites co-located with adjacent warehousing and office space. An
onsite engineering laboratory will help customers develop turnkey
production platforms that enable them to rapidly transition to
commercial-scale operations when ready. As with its other viral
vector development and manufacturing sites, Thermo Fisher's Plainville site will attract a diverse
workforce of scientists, quality control specialists and production
teams.
Thermo Fisher strategically
selected Plainville to capitalize
on its expertise at other Massachusetts locations and draw upon the
strong talent pool in the Greater
Boston area. The state-of-the-art facility will feature
digital connectivity and capabilities that enable operational
efficiencies, high quality, data visibility and advanced operator
training.
Lagarde added, "The global race to develop new transformative
medicines illustrates how important it is for our customers to have
access to surge capacity as well as flexibility to adapt and change
therapeutic platforms, whether they are developing a new viral
vector for a novel therapy or the next life-saving cancer
treatment."
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue exceeding $25
billion. Our Mission is to enable our customers to make the
world healthier, cleaner and safer. Whether our customers are
accelerating life sciences research, solving complex analytical
challenges, improving patient diagnostics and therapies or
increasing productivity in their laboratories, we are here to
support them. Our global team of more than 75,000 colleagues
delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and
Patheon. For more information, please visit
www.thermofisher.com.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-double-its-capacity-of-viral-vector-manufacturing-301056352.html
SOURCE Thermo Fisher Scientific